Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer

ObjectivesExisting prognostic risk assessment strategies for prostate cancer (PCa) remain unsatisfactory. Similar treatments for patients at the same disease stage can lead to different survival outcomes. Thus, we aimed to explore a novel immune landscape-based prognostic predictor and therapeutic t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yanting Shen, Huan Xu, Manmei Long, Miaomiao Guo, Peizhang Li, Ming Zhan, Zhong Wang
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	prognostic predictor immune infiltration progression-free survival (PFS) overall survival (OS) prostate cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1405a8c475bd4743b7fed464c9dd1d26
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1405a8c475bd4743b7fed464c9dd1d26
record_format	dspace
spelling	oai:doaj.org-article:1405a8c475bd4743b7fed464c9dd1d262021-11-05T11:32:19ZScreening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer2234-943X10.3389/fonc.2021.761643https://doaj.org/article/1405a8c475bd4743b7fed464c9dd1d262021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.761643/fullhttps://doaj.org/toc/2234-943XObjectivesExisting prognostic risk assessment strategies for prostate cancer (PCa) remain unsatisfactory. Similar treatments for patients at the same disease stage can lead to different survival outcomes. Thus, we aimed to explore a novel immune landscape-based prognostic predictor and therapeutic target for PCa patients.MethodsA total of 490 PCa patients from The Cancer Genome Atlas Project (TCGA) cohort were analyzed to obtain immune landscape-based prognostic features. Then, analyses at different levels were performed to explore the relevant survival mechanisms, prognostic predictors, and therapeutic targets. Finally, experimental verification was performed using a tissue microarray (TMA) from 310 PCa patients. Furthermore, a nomogram was constructed to provide a quantitative approach for predicting the prognosis of patients with PCa.ResultsThe immune landscape-based risk score (ILBRS) was obtained. Then, VAV1, which presented a significant positive correlation with Treg infiltration and ILBRS, was screened and identified to be significantly related to the prognosis of PCa. Finally, experimental verification confirmed the prognostic value of VAV1 for PCa prognosis at the protein level.ConclusionsVAV1 has the potential to be developed as an immune landscape-based PCa prognostic predictor and therapeutic target and will help improve prognosis by enabling the selection of individualized, targeted therapy.Yanting ShenHuan XuManmei LongMiaomiao GuoPeizhang LiMing ZhanMing ZhanZhong WangFrontiers Media S.A.articleprognostic predictorimmune infiltrationprogression-free survival (PFS)overall survival (OS)prostate cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	prognostic predictor immune infiltration progression-free survival (PFS) overall survival (OS) prostate cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	prognostic predictor immune infiltration progression-free survival (PFS) overall survival (OS) prostate cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yanting Shen Huan Xu Manmei Long Miaomiao Guo Peizhang Li Ming Zhan Ming Zhan Zhong Wang Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer
description	ObjectivesExisting prognostic risk assessment strategies for prostate cancer (PCa) remain unsatisfactory. Similar treatments for patients at the same disease stage can lead to different survival outcomes. Thus, we aimed to explore a novel immune landscape-based prognostic predictor and therapeutic target for PCa patients.MethodsA total of 490 PCa patients from The Cancer Genome Atlas Project (TCGA) cohort were analyzed to obtain immune landscape-based prognostic features. Then, analyses at different levels were performed to explore the relevant survival mechanisms, prognostic predictors, and therapeutic targets. Finally, experimental verification was performed using a tissue microarray (TMA) from 310 PCa patients. Furthermore, a nomogram was constructed to provide a quantitative approach for predicting the prognosis of patients with PCa.ResultsThe immune landscape-based risk score (ILBRS) was obtained. Then, VAV1, which presented a significant positive correlation with Treg infiltration and ILBRS, was screened and identified to be significantly related to the prognosis of PCa. Finally, experimental verification confirmed the prognostic value of VAV1 for PCa prognosis at the protein level.ConclusionsVAV1 has the potential to be developed as an immune landscape-based PCa prognostic predictor and therapeutic target and will help improve prognosis by enabling the selection of individualized, targeted therapy.
format	article
author	Yanting Shen Huan Xu Manmei Long Miaomiao Guo Peizhang Li Ming Zhan Ming Zhan Zhong Wang
author_facet	Yanting Shen Huan Xu Manmei Long Miaomiao Guo Peizhang Li Ming Zhan Ming Zhan Zhong Wang
author_sort	Yanting Shen
title	Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer
title_short	Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer
title_full	Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer
title_fullStr	Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer
title_full_unstemmed	Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer
title_sort	screening to identify an immune landscape-based prognostic predictor and therapeutic target for prostate cancer
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/1405a8c475bd4743b7fed464c9dd1d26
work_keys_str_mv	AT yantingshen screeningtoidentifyanimmunelandscapebasedprognosticpredictorandtherapeutictargetforprostatecancer AT huanxu screeningtoidentifyanimmunelandscapebasedprognosticpredictorandtherapeutictargetforprostatecancer AT manmeilong screeningtoidentifyanimmunelandscapebasedprognosticpredictorandtherapeutictargetforprostatecancer AT miaomiaoguo screeningtoidentifyanimmunelandscapebasedprognosticpredictorandtherapeutictargetforprostatecancer AT peizhangli screeningtoidentifyanimmunelandscapebasedprognosticpredictorandtherapeutictargetforprostatecancer AT mingzhan screeningtoidentifyanimmunelandscapebasedprognosticpredictorandtherapeutictargetforprostatecancer AT mingzhan screeningtoidentifyanimmunelandscapebasedprognosticpredictorandtherapeutictargetforprostatecancer AT zhongwang screeningtoidentifyanimmunelandscapebasedprognosticpredictorandtherapeutictargetforprostatecancer
_version_	1718444271613247488

Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer

Ejemplares similares